| ID Source | ID |
|---|---|
| PubMed CID | 3014024 |
| CHEMBL ID | 502109 |
| SCHEMBL ID | 631295 |
| MeSH ID | M0350978 |
| Synonym |
|---|
| zephiran |
| NCGC00095057-01 |
| NCGC00095057-02 |
| SPECTRUM1503610 |
| einecs 216-695-0 |
| HMS2093G19 |
| benzyldimethyl(tridecyl)ammonium chloride |
| HMS502J07 |
| nsc-758480 |
| CHEMBL502109 |
| alpagelle |
| pentonium |
| benzalkonii chloridum |
| HMS1922E14 |
| benzenemethanaminium, ar-dodecyl-n,n,n-trimethyl-, chloride (1:1) |
| pharmakon1600-01503610 |
| nsc758480 |
| CCG-39344 |
| 1641-93-6 |
| SCHEMBL631295 |
| dimethylbenzyl tridecyl ammonium chloride |
| XIWFQDBQMCDYJT-UHFFFAOYSA-M |
| benzenemethanaminium, n,n-dimethyl-n-tridecyl-, chloride |
| SR-05000001862-1 |
| sr-05000001862 |
| tridecyldimethylbenzylammonium chloride |
| DTXSID70936908 |
| n-benzyl-n,n-dimethyltridecan-1-aminium chloride |
| benzyl-dimethyl-tridecylazanium;chloride |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 56.2341 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 56.2341 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 0.6159 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| 67.9K protein | Vaccinia virus | Potency | 11.2202 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 19.9526 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 14.2191 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.1969 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 11.2202 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 15.8489 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID338703 | Antimicrobial activity against Escherichia coli ATCC 8739 | |||
| AID338702 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 9027 | |||
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1150900 | Binding affinity to bovine serum albumin after overnight incubation by equilibrium dialysis | 1976 | Journal of medicinal chemistry, Jun, Volume: 19, Issue:6 | Effect of chain length on critical micelle formation and protein binding of quaternary ammonium compounds. |
| AID1150899 | Critical micelle concentration of the compound | 1976 | Journal of medicinal chemistry, Jun, Volume: 19, Issue:6 | Effect of chain length on critical micelle formation and protein binding of quaternary ammonium compounds. |
| AID338705 | Antimicrobial activity against Candida albicans ATCC 10231 | |||
| AID338704 | Antimicrobial activity against Staphylococcus aureus ATCC 6538 | |||
| AID1726848 | Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by microdilution method | 2021 | RSC medicinal chemistry, Jun-23, Volume: 12, Issue:6 | Sulfonium-based liposome-encapsulated antibiotics deliver a synergistic antibacterial activity. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (44.70) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||